This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ikeda, Y. Articles by Majima, M. Search for Related Content PubMed PubMed Citation Articles by Ikeda, Y. Articles by Majima, M.

Host Stromal Bradykinin B₂ Receptor Signaling Facilitates Tumor-Associated Angiogenesis and Tumor Growth

¹ Department of Molecular Pharmacology, Kitasato University Graduate School of Medical Sciences, Kanagawa, Japan; Departments of ² Obstetrics and Gynecology, ³ Pharmacology, and ⁴ Anatomy, Kitasato University School of Medicine, Kanagawa, Japan; and ⁵ Department of Medicine II, Kansai Medical University, Osaka, Japan

We evaluated the significance of the host kallikrein-kinin system in tumor angiogenesis and tumor growth using two rodent models genetically deficient in a kallikrein-kinin system. Inoculation of Walker 256 carcinoma cells into the s.c. tissues of the back of normal Brown Norway Kitasato rats (BN-Ki rats) resulted in the rapid development of solid tumors with marked angiogenesis. By contrast, in kininogen-deficient Brown Norway Katholiek rats (BN-Ka rats), which cannot generate intrinsic bradykinin (BK), the weights of the tumors and the extent of angiogenesis were significantly less than those in BN-Ki rats. Daily administration of B₂ receptor antagonists significantly reduced angiogenesis and tumor weights in BN-Ki rats to levels similar to those in BN-Ka rats but did not do so in BN-Ka rats. Angiogenesis and tumor growth were significantly suppressed in B₂ receptor knockout mice bearing sarcoma 180 compared with their wild-type counterparts. Immunoreactive vascular endothelial growth factor (VEGF) was localized in Walker tumor stroma more extensively in BN-Ki rats than in BN-Ka rats, although immunoreactive B₂ receptor also was detected in the stroma to the same extent in both types of rats. Cultured stromal fibroblasts isolated from BN-Ki rats and BN-Ka rats produced VEGF in response to BK (10^–8-10^–6 M), and this stimulatory effect of BK was abolished with a B₂ receptor antagonist, Hoe140 (10^–5 M). These results suggest that BK generated from kininogens supplied from the host may facilitate tumor-associated angiogenesis and tumor growth by stimulating stromal B₂ signaling to up-regulate VEGF production mainly in fibroblasts.

This article has been cited by other articles:

				M. Bader Kallikrein-Kinin System in Neovascularization Arterioscler. Thromb. Vasc. Biol., May 1, 2009; 29(5): 617 - 619. [Full Text] [PDF]

				A. Ribeiro-Oliveira Jr, G. Franchi, B. Kola, P. Dalino, S. V. B. Pinheiro, N. Salahuddin, M. Musat, M. I Goth, S. Czirjak, Z. Hanzely, et al. Protein western array analysis in human pituitary tumours: insights and limitations Endocr. Relat. Cancer, December 1, 2008; 15(4): 1099 - 1114. [Abstract] [Full Text] [PDF]

				W. Zhang, N. Bhola, S. Kalyankrishna, W. Gooding, J. Hunt, R. Seethala, J. R. Grandis, and J. M. Siegfried Kinin B2 Receptor Mediates Induction of Cyclooxygenase-2 and Is Overexpressed in Head and Neck Squamous Cell Carcinomas Mol. Cancer Res., December 1, 2008; 6(12): 1946 - 1956. [Abstract] [Full Text] [PDF]

				Y.-Y. Yao, H. Yin, B. Shen, R. S. Smith Jr, Y. Liu, L. Gao, L. Chao, and J. Chao Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3{beta} pathway Cardiovasc Res, December 1, 2008; 80(3): 354 - 364. [Abstract] [Full Text] [PDF]

				L. Sanchez de Miguel, S. Neysari, S. Jakob, M. Petrimpol, N. Butz, A. Banfi, C. E. Zaugg, R. Humar, and E. J. Battegay B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart Cardiovasc Res, October 1, 2008; 80(1): 106 - 113. [Abstract] [Full Text] [PDF]

				R. D. Loberg, C. Ying, M. Craig, L. L. Day, E. Sargent, C. Neeley, K. Wojno, L. A. Snyder, L. Yan, and K. J. Pienta Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo Cancer Res., October 1, 2007; 67(19): 9417 - 9424. [Abstract] [Full Text] [PDF]

				N. Petrovic, W. Schacke, J. R. Gahagan, C. A. O'Conor, B. Winnicka, R. E. Conway, P. Mina-Osorio, and L. H. Shapiro CD13/APN regulates endothelial invasion and filopodia formation Blood, July 1, 2007; 110(1): 142 - 150. [Abstract] [Full Text] [PDF]

				N. Nagai, Y. Oike, K. Izumi-Nagai, T. Koto, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, et al. Suppression of Choroidal Neovascularization by Inhibiting Angiotensin-Converting Enzyme: Minimal Role of Bradykinin Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2321 - 2326. [Abstract] [Full Text] [PDF]

				E. Kamoshita, Y. Ikeda, M. Fujita, H. Amano, A. Oikawa, T. Suzuki, Y. Ogawa, S. Yamashina, S. Azuma, S. Narumiya, et al. Recruitment of a Prostaglandin E Receptor Subtype, EP3-Expressing Bone Marrow Cells Is Crucial in Wound-Induced Angiogenesis Am. J. Pathol., October 1, 2006; 169(4): 1458 - 1472. [Abstract] [Full Text] [PDF]

				M. Muta, G. Matsumoto, E. Nakashima, and M. Toi Mechanical Analysis of Tumor Growth Regression by the Cyclooxygenase-2 Inhibitor, DFU, in a Walker256 Rat Tumor Model: Importance of Monocyte Chemoattractant Protein-1 Modulation Clin. Cancer Res., January 1, 2006; 12(1): 264 - 272. [Abstract] [Full Text] [PDF]